Reuters logo
BRIEF-Soligenix receives European patent for formulation of synthetic hypericin to treat psoriasis
February 22, 2017 / 11:13 AM / 9 months ago

BRIEF-Soligenix receives European patent for formulation of synthetic hypericin to treat psoriasis

Feb 22 (Reuters) - Soligenix Inc

* Soligenix Inc - Proprietary formulation of synthetic hypericin has been granted a European patent for treatment of psoriasis

* Soligenix Inc - Currently enrolling patients into a pivotal Phase 3 clinical trial of SGX301 for treatment of CTCL

* Soligenix Inc - Results of ongoing Phase 3 CTCL clinical study are expected by end of this year Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below